Arkolith/Insider Trading/ABUS/Form 4

McElhaugh Michael J.

Interim President & CEO, DirectorArbutus Biopharma Corp (ABUS) · full profile →Form 4 · filed Feb 5, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$78K
Net Open-Market Flow
-$78K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 4, 2025Sell(S)24K$3.28$78K1.5M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001447028-25-000038) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML